pharmazac-logopharmazac-logopharmazac-logopharmazac-logo
  • Our Company
    • Our Identity
      • Who We Are
      • Our History
      • Our Philosophy
      • Our Numbers
    • Our Corporate Structure
      • Our Divisions
      • Our Sites
      • Our Management
      • Our People
      • Our Partnerships
    • Our International Presence
      • Our Exports
      • International Licensing
      • Our Subsidiaries
      • DIAGNOZ Plc
    • Strategy & Investments
      • Our Strategy
      • Our PHARMAZAC 50 Vision
      • Our Research & Development
  • Our Science
    • Generic Pharmaceuticals (Gx)
      • Generics
      • Our R&D Laboratories
      • Our Projects
    • Innovative Generics (Gx+)
      • Our Innovation Strategy
      • Our Innovative Projects
    • Diagnostics &
      Radiopharmaceuticals (PDx)
      • Contrast Media
      • Nuclear Medicine
      • Radiopharmaceuticals
      • Theranostics
    • Pharma Manufacturing & QC
      • Solid Forms
      • Nasal Sprays
      • Sterile (Radiopharma)
      • Logistics Operations
      • Quality Control & Release Labs
  • Our Products & Services
    • Our Products in Greece
    • Our International Dossiers
    • Our Diagnostics
    • Our CMO/CDMO Services
  • Our News Hub
  • Your Career
  • Contact
  • EN
0

$0.00

EN
✕

Our International Dossiers

  • Home
  • Our International Dossiers

PHARMAZAC International Dossiers
Vortioxetine
Vortioxetine
Sacubitril + Valsartan + Dapagliflozin
Sacubitril + Valsartan + Dapagliflozin
Resmetirom
Resmetirom
Mavacamten
Mavacamten
Iron sucrose
Iron sucrose
Finerenone
Finerenone
Fezolinetant
Fezolinetant
Ferric carboxymaltose
Ferric carboxymaltose
Edoxaban
Edoxaban
Daridorexant
Daridorexant
Brexpiprazole
Brexpiprazole
Aripiprazole
Aripiprazole
123

Follow us

Headquarters, Pharmaceutical Manufacturing Site & R&D Lab

1, A. Zaroliagki & 6, D. Lamprou Str.
GR-19001 Keratea
Greece
Center: +30 210 3418889-97
e-mail: pharmazac@pharmazac.com

Radiopharmaceutical Manufacturing Site

Lamia Industrial Zone, 3 & 3A Str.
OT 4B, GR-35100 Lamia
Greece
Center: +30 210 3418889-95

Report an Adverse Event / Pharmacovigilance

For any adverse event report
please contact Errietta Economou,
Head of Vigilance
Mobile: +30 6946463306 (24/7)
e-mail: eeconomou@vigi-care.eu

Corporate Statements and Publications

  • Media Material
  • Corporate Presentation
  • CMO/CDMO Services
© 2026 | All Rights Reserved
Web Design & Development by Generation Y
0

$0.00

EN
  • No translations available for this page
✕

Login

Lost your password?

Greece 2.0 - Next Generation EU Learn More